Microgynon 21
Główne informacje
- Nazwa własna:
- Microgynon 21 30 mcg + 150 mcg tabletki powlekane
- Dostępny od:
- Forfarm Sp. z o.o.
- Kod ATC:
- G03AA07
- INN (International Nazwa):
- Ethinylestradiolum + Levonorgestrelum
- Dawkowanie:
- 30 mcg + 150 mcg
- Forma farmaceutyczna:
- tabletki powlekane
- Używać do:
- Ludzie
- Typ medycyny:
- alopatycznych narkotyków
Dokumenty
- dla ogółu społeczeństwa:
- Ulotka informacyjna dla tego produktu nie są obecnie dostępne, można wysłać żądanie do obsługi klienta, a poinformujemy Cię, jak tylko jesteśmy w stanie go uzyskać.
Prośba o ulotkę informacyjną dla ogółu społeczeństwa.
- dla pracowników służby zdrowia:
- Ulotka informacyjna dla tego produktu nie są obecnie dostępne, można wysłać żądanie do obsługi klienta, a poinformujemy Cię, jak tylko jesteśmy w stanie go uzyskać.
Prośba o ulotkę informacyjną dla pracowników służby zdrowia.
Lokalizacja
- Dostępne w:
-
Polska
- Język:
- polski
Informacje terapeutyczne
- Podsumowanie produktu:
- 21 tabl., 5909997010366, Rp; 63 tabl., 5909997010373, Rp
Inne informacje
Status
- Źródło:
- Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych
- Numer pozwolenia:
- 151/08
- Ostatnia aktualizacja:
- 17-03-2018
- Ulotka informacyjna dla tego produktu nie są obecnie dostępne, można wysłać żądanie do obsługi klienta, a poinformujemy Cię, jak tylko jesteśmy w stanie go uzyskać.
Prośba o ulotkę informacyjną dla ogółu społeczeństwa.
- Dostęp do tego dokumentu jest możliwy tylko dla zarejestrowanych użytkowników.
Zarejestruj się teraz za pełny dostęp
21-2-2019
February 21, 2019: Traveling Nurse Who Worked in Roanoke Sentenced for Tampering with Fentanyl
February 21, 2019: Traveling Nurse Who Worked in Roanoke Sentenced for Tampering with Fentanyl
FDA - U.S. Food and Drug Administration
20-2-2019
Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 February 2019, European Medicines Agency, from 19/02/2019 to 21/02/2019
Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 February 2019, European Medicines Agency, from 19/02/2019 to 21/02/2019
Europe - EMA - European Medicines Agency
26-1-2019
SL: Recall of Thrive Market Nut Butters Due to Potential Health Risk
Thrive Market, Inc, is recalling all unexpired lots of the Thrive Market-branded nut butters listed below (“Product(s)”) due to the potential for contamination with Listeria monocytogenes. On January 21, 2019, one of our suppliers notified us that it was issuing a recall of all nut butters it has manufactured since January 2018 because of a positive test for Listeria monocytogenes in recent lots. Because the safety of our members is our absolute priority, we are expanding on our supplier’s recall and a...
FDA - U.S. Food and Drug Administration
22-1-2019
Modification of the existing maximum residue level for trifloxystrobin in broccoli
Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer Hellas AG submitted a request to the competent national authority in Greece to modify the existing maximum residue level (MRL) for the active substance trifloxystrobin in broccoli. The data submitted in support of the request were found to be sufficient to derive an MRL proposal for broccoli. Adequate analytical methods for enforcement are available to control the residues of trifloxystrobin o...
Europe - EFSA - European Food Safety Authority EFSA Journal
22-1-2019
Modification of the existing maximum residue levels for aclonifen in celeriacs and certain fresh herbs
Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicants Landesanstalt für Landwirtschaft und Gartenbau Sachsen‐Anhalt (LSA) and Dienstleistungszentrum Ländlicher Raum Rheinpfalz (DLR), respectively, submitted a request to the competent national authority in Germany to modify the existing maximum residue levels (MRL) for the active substance aclonifen in chives, parsley, celery leaves/dill leaves, thyme/savoury and in celeriacs/turnip‐rooted celery. The ...
Europe - EFSA - European Food Safety Authority EFSA Journal
22-1-2019
Modification of the existing maximum residue levels for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds
Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Isagro S.p.A submitted a request to the competent national authority in Italy to modify the existing maximum residue levels (MRLs) for the active substance tetraconazole in various crops and animal commodities. The data submitted in support of the request were found to be sufficient to derive MRL proposals for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds. Adequate analytical me...
Europe - EFSA - European Food Safety Authority EFSA Journal
22-1-2019
SIGMA Animal Disease Data Model: A comprehensive approach for the collection of standardised data on animal diseases
Published on: Mon, 21 Jan 2019 The European Commission is routinely asking EFSA for scientific and technical support in the epidemiological analysis of animal disease outbreaks (i.e. African swine fever, lumpy skin disease and avian influenza) and to report or assess surveillance data (i.e. Echinococcus multilocularis and avian influenza). For this purpose, EFSA has over the last years carried out several data collections and gathered specific information on outbreaks, surveillance activities and concer...
Europe - EFSA - European Food Safety Authority EFSA Journal
22-1-2019
Data sources on animal diseases: Country Card of Ireland
Published on: Mon, 21 Jan 2019 Mapping ‘data sources’ on animal diseases in each European Union (EU) Member State is one of the activities of EFSA's SIGMA1,2 ;project. The aim of this activity is to identify the central competent authorities responsible for managing the data on animal diseases and animal populations in each Member State. Initially EFSA is focusing on three diseases (on which EFSA is currently working): African swine fever, avian influenza and lumpy skin disease; and on the corresponding...
Europe - EFSA - European Food Safety Authority EFSA Journal
22-1-2019
Peer review of the pesticide risk assessment of the active substance fenamiphos
Published on: Mon, 21 Jan 2019 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State Greece and co‐rapporteur Member State Cyprus for the pesticide active substance fenamiphos are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of fenamiphos as a nematic...
Europe - EFSA - European Food Safety Authority EFSA Journal
22-1-2019
Modification of the existing maximum residue levels for aminopyralid in certain cereals
Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Dow AgroSciences Denmark submitted a request to the competent national authority in the United Kingdom to modify the existing maximum residue levels (MRLs) for the active substance aminopyralid in cereals. The data submitted in support of the request were found to be sufficient to derive MRL proposals for barley, rye, sorghum, millet and oats. A modification of the existing MRL of aminopyralid in wh...
Europe - EFSA - European Food Safety Authority EFSA Journal
21-1-2019
Enforcement Report for the Week of January 09, 2019
Recently Updated Records for the Week of January 09, 2019 Last Modified Date: Monday, January 21, 2019
FDA - U.S. Food and Drug Administration
19-1-2019
Ottogi America, Inc. Issues Allergy Alert on Undeclared Egg in Products
Ottogi America, Inc. announced today it is recalling below 21 items due to a possibility of containing egg ingredient undeclared on the packages. People who have an allergy or severe sensitivity to eggs run the risk of serious or life-threatening allergic reaction of they consume these products.
FDA - U.S. Food and Drug Administration
26-12-2018
Enforcement Report for the Week of December 26, 2018
Recently Updated Records for the Week of December 26, 2018 Last Modified Date: Friday, December 21, 2018
FDA - U.S. Food and Drug Administration
22-12-2018
Modification of the existing maximum residue level for captan in hops
Published on: Fri, 21 Dec 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant ADAMA Agriculture BV on behalf of ADAMA Makhteshim Ltd. submitted a request to the competent national authority in the Netherlands to modify the existing maximum residue level for the active substance captan in hops. The data submitted in support of the request were found to be insufficient to conclude whether the existing residue definitions are appropriate for hops. Although the number of residue ...
Europe - EFSA - European Food Safety Authority EFSA Journal
22-12-2018
Modification of the existing maximum residue level for captan in cranberries
Published on: Fri, 21 Dec 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the Belgian Federal Public Service (FPS) for Health, Food chain safety and Environment, submitted an application as the competent national authority in Belgium to modify the existing maximum residue level (MRL) for the active substance captan in cranberries. The data submitted in support of the request were found to be sufficient to derive MRL proposal for cranberries. Adequate analytical methods for enforcement ...
Europe - EFSA - European Food Safety Authority EFSA Journal
14-12-2018
Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection
Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...
Europe - EFSA - European Food Safety Authority Publications
30-11-2018
The European Union summary report on surveillance for the presence of transmissible spongiform encephalopathies (TSEs) in 2017
Published on: Thu, 29 Nov 2018 This report presents the results of surveillance on transmissible spongiform encephalopathies (TSEs) in bovine animals, sheep, goats, cervids and other animal species, as well as genotyping in sheep, carried out in 2017 in the European Union (EU) according to Regulation (EC) 999/2001, and in Iceland, Norway and Switzerland. In total, 1,312,714 cattle were tested by the 28 EU Member States (MSs) which is a decrease of 3% compared with 2016; 18,526 were tested by the three n...
Europe - EFSA - European Food Safety Authority Publications
22-11-2018
Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening
Published on: Wed, 21 Nov 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed. Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed...
Europe - EFSA - European Food Safety Authority Publications
21-2-2019
Orphan designation: Chimeric monoclonal antibody against GD2 (dinutuximab), Treatment of neuroblastoma, 21/06/2011, Withdrawn
Orphan designation: Chimeric monoclonal antibody against GD2 (dinutuximab), Treatment of neuroblastoma, 21/06/2011, Withdrawn
Europe - EMA - European Medicines Agency
21-2-2019
Orphan designation: Celecoxib, Treatment of familial adenomatous polyposis (FAP), 21/11/2001, Withdrawn
Orphan designation: Celecoxib, Treatment of familial adenomatous polyposis (FAP), 21/11/2001, Withdrawn
Europe - EMA - European Medicines Agency
13-2-2019
Orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide, Treatment of cystic fibrosis, 21/05/2015, Positive
Orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide, Treatment of cystic fibrosis, 21/05/2015, Positive
Europe - EMA - European Medicines Agency
7-2-2019
Consultation: Reforms to the generic medicine market authorisation process
The TGA is seeking comments from interested parties on the proposed generic medicines reforms. Closing date: 21 March 2019
Therapeutic Goods Administration - Australia
25-1-2019
Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive
Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive
Europe - EMA - European Medicines Agency
25-1-2019
Orphan designation: Triamcinolone acetonide, Treatment of non-infectious uveitis, 21/05/2015, Positive
Orphan designation: Triamcinolone acetonide, Treatment of non-infectious uveitis, 21/05/2015, Positive
Europe - EMA - European Medicines Agency
22-1-2019
Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive
Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive
Europe - EMA - European Medicines Agency
21-1-2019
bimatoprost
bimatoprost (Active substance: bimatoprost) - Centralised - Art 28 - (PSUR - Commission Decision C(2019) 591 of Mon, 21 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/413/201803
Europe -DG Health and Food Safety
21-1-2019
Diclofenac Sodium Spray Gel 4 % Cutaneous Spray, Solution and associated names
Diclofenac Sodium Spray Gel 4 % Cutaneous Spray, Solution and associated names (Active substance: Diclofenac sodium) - Community Referrals - Art 29 - Commission Decision (2019)589 of Mon, 21 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/A-29(4)/1467
Europe -DG Health and Food Safety
17-1-2019
Holoclar (Chiesi Farmaceutici S.p.A.)
Holoclar (Active substance: Ex vivo expanded autologous human corneal epithelial cells containing stem cells) - Centralised - Annual renewal - Commission Decision (2019)272 of Thu, 17 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2450/R/21
Europe -DG Health and Food Safety
16-1-2019
EU/3/14/1309 (Pharma Gateway AB)
EU/3/14/1309 (Active substance: 17a,21-dihydroxy-16a-methyl-pregna-1,4,9(11)-triene-3,20-dione) - Transfer of orphan designation - Commission Decision (2019)232 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002736
Europe -DG Health and Food Safety
19-12-2018
EU/3/14/1423 (Richardson Associates Regulatory Affairs Ltd)
EU/3/14/1423 (Active substance: Synthetic signal peptide of human mucin-1 (amino acids 1-21)) - Transfer of orphan designation - Commission Decision (2018)9009 of Wed, 19 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002647
Europe -DG Health and Food Safety
19-12-2018
European Medicines Agency closed 21 December 2018 to 2 January 2019
European Medicines Agency closed 21 December 2018 to 2 January 2019
Europe - EMA - European Medicines Agency
18-12-2018
EU/3/18/2108 (Pharma Gateway AB)
EU/3/18/2108 (Active substance: Adeno-associated viral vector expressing human 21-hydroxylase) - Orphan designation - Commission Decision (2018)9023 of Tue, 18 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/140/18
Europe -DG Health and Food Safety
12-12-2018
Consultation: Proposed amendments to the Poisons Standard - ACCS, ACMS and Joint ACCS/ACMS meetings, March 2019
Proposed Amendments to the Poisons Standard are now available for public comment. Closing date: 21 January 2019
Therapeutic Goods Administration - Australia
12-12-2018
Oncaspar (Les Laboratoires Servier)
Oncaspar (Active substance: pegaspargase) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8757 of Wed, 12 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3789/T/21
Europe -DG Health and Food Safety
12-12-2018
Elocta (Swedish Orphan Biovitrum AB (publ))
Elocta (Active substance: efmoroctocog alfa) - Centralised - Variation - Commission Decision (2018)8678 of Wed, 12 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3964/X/21
Europe -DG Health and Food Safety
26-11-2018
Mirvaso (Galderma International)
Mirvaso (Active substance: brimonidine) - Centralised - Renewal - Commission Decision (2018)7977 of Mon, 26 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2642/R/21
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2081 (Pharma Gateway AB)
EU/3/18/2081 (Active substance: 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid) - Orphan designation - Commission Decision (2018)7790 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/096/18
Europe -DG Health and Food Safety
21-11-2018
Rheumocam (Chanelle Pharmaceuticals Manufacturing Limited)
Rheumocam (Active substance: Meloxicam) - Centralised - Variation - Commission Decision (2018)7841 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/121/X/22
Europe -DG Health and Food Safety
21-11-2018
EU/3/15/1567 (TMC Pharma (EU) Limited)
EU/3/15/1567 (Active substance: Recombinant human interleukin-3 truncated diphtheria toxin fusion protein) - Transfer of orphan designation - Commission Decision (2018)7816 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/064/15/T/02
Europe -DG Health and Food Safety
21-11-2018
EU/3/17/1962 (MWB Consulting S.A.R.L.)
EU/3/17/1962 (Active substance: Humanised Fc-engineered monoclonal antibody against CD19) - Transfer of orphan designation - Commission Decision (2018)7815 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/155/17/T/01
Europe -DG Health and Food Safety
21-11-2018
Osurnia (Elanco GmbH)
Osurnia (Active substance: terbinafine / florfenicol / betamethasone acetate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)7842 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/003753/T/0010
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2102 (IQVIA RDS Ireland Limited)
EU/3/18/2102 (Active substance: Apraglutide) - Orphan designation - Commission Decision (2018)7812 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/115/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2101 (TMC Pharma Services Ltd)
EU/3/18/2101 (Active substance: Setmelanotide) - Orphan designation - Commission Decision (2018)7811 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/143/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2100 (Quality Regulatory Clinical Ireland Limited)
EU/3/18/2100 (Active substance: Propagermanium) - Orphan designation - Commission Decision (2018)7810 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/103/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2099 (Celgene Europe Limited)
EU/3/18/2099 (Active substance: Lisocabtagene maraleucel) - Orphan designation - Commission Decision (2018)7809 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/124/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2098 (Bayer AG)
EU/3/18/2098 (Active substance: Larotrectinib) - Orphan designation - Commission Decision (2018)7808 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/117/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2097 (Bayer AG)
EU/3/18/2097 (Active substance: Larotrectinib) - Orphan designation - Commission Decision (2018)7807 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/116/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2096 (Hansa Medical AB)
EU/3/18/2096 (Active substance: Imlifidase) - Orphan designation - Commission Decision (2018)7806 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/093/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2095 (United Neuroscience Limited)
EU/3/18/2095 (Active substance: Ile-Ser-Ile-Thr-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Ile-Glu-Thr-Ile-Leu-Phe-Lys-Lys-Lys-Lys-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr-Gln-Asp) - Orphan designation - Commission Decision (2018)7805 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/146/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2094 (Y-mAbs Therapeutics A/S)
EU/3/18/2094 (Active substance: Anti-GD2 monoclonal antibody 3F8 humanised) - Orphan designation - Commission Decision (2018)7804 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/126/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2093 (Sanquin Plasma Products B.V.)
EU/3/18/2093 (Active substance: Human apotransferrin) - Orphan designation - Commission Decision (2018)7803 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/109/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2092 (Dr Regenold GmbH)
EU/3/18/2092 (Active substance: H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-213-bismuth) - Orphan designation - Commission Decision (2018)7802 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/145/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2091 (Pharma Gateway AB)
EU/3/18/2091 (Active substance: Glucagon) - Orphan designation - Commission Decision (2018)7801 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/108/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2090 (Pfizer Europe MA EEIG)
EU/3/18/2090 (Active substance: Fidanacogene elaparvovec) - Orphan designation - Commission Decision (2018)7799 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/112/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2087 (Consejo Superior de Investigaciones Cientificas (CSIC))
EU/3/18/2087 (Active substance: Etamsylate) - Orphan designation - Commission Decision (2018)7796 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/135/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2086 (Santhera Pharmaceuticals (Deutschland) GmbH)
EU/3/18/2086 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate) - Orphan designation - Commission Decision (2018)7795 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/106/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2085 (Rigenerand S.r.l.)
EU/3/18/2085 (Active substance: Autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand) - Orphan designation - Commission Decision (2018)7794 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/110/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2084 (Bayer AG)
EU/3/18/2084 (Active substance: Anetumab ravtansine) - Orphan designation - Commission Decision (2018)7793 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/258/17
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2083 (MaaT PHARMA)
EU/3/18/2083 (Active substance: Allogeneic faecal microbiota, pooled) - Orphan designation - Commission Decision (2018)7792 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/123/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2082 (Takeda Pharma A/S)
EU/3/18/2082 (Active substance: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride) - Orphan designation - Commission Decision (2018)7791 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/040/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/08/556 (Vertex Pharmaceuticals (Ireland) Limited)
EU/3/08/556 (Active substance: N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide) - Transfer of orphan designation - Commission Decision (2018)7814 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/08/T/03
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2089 (Dystrogen Therapeutics S.A.)
EU/3/18/2089 (Active substance: Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor) - Orphan designation - Commission Decision (2018)7798 of Wed, 21 Nov 2018
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2088 (Dystrogen Therapeutics S.A.)
EU/3/18/2088 (Active substance: Ex vivo fused normal allogeneic human myoblast with another normal allogeneic human myoblast) - Orphan designation - Commission Decision (2018)7797 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/134/18
Europe -DG Health and Food Safety
21-11-2018
EU/3/17/1923 (Pfizer Europe MA EEIG)
EU/3/17/1923 (Active substance: Glasdegib maleate) - Transfer of orphan designation - Commission Decision (2018)7839 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/106/17/T/01
Europe -DG Health and Food Safety